行情

CFRX

CFRX

ContraFect
NASDAQ

实时行情|Nasdaq Last Sale

0.3950
-0.0069
-1.72%
盘后: 0.3950 0 0.00% 16:41 09/13 EDT
开盘
0.3900
昨收
0.4019
最高
0.4099
最低
0.3801
成交量
10.43万
成交额
--
52周最高
2.629
52周最低
0.2693
市值
3,136.68万
市盈率(TTM)
7.18
分时
5日
1月
3月
1年
5年

分析师评级

4位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

CFRX 新闻

  • 别急着抢iPhone 苹果已盯上你未来十年的钱
  • 新浪财经综合.3小时前
  • 绝不延迟脱欧 英首相自比"绿巨人":越疯狂,就越强大
  • 环球网.5小时前
  • 沙特石油设施遇袭产量减半 美随时准备动用石油储备
  • 新京报网.6小时前
  • 新华国际时评:央行“放水”恐难纾欧元区之困
  • 新华网.6小时前

更多

所属板块

生物技术和医学研究
+0.20%
制药与医学研究
-0.38%

热门股票

名称
价格
涨跌幅

CFRX 简况

ContraFect Corporation is a clinical-stage biotechnology company. The Company is focused on discovering and developing therapeutic protein and antibody products for the treatment of infectious diseases, including those caused by drug-resistant pathogens, particularly those treated in hospital settings. Its pipeline of lysin candidates includes CF-301, CF-302, CF-303, CF-309, CF-304, CF-305, CF-306, CF-307 and CF-308. Its other product candidate includes CF-404. Its lysin product candidate, CF-301 is developed for the treatment of Staph aureus bacteremia, including endocarditis, caused by methicillin-resistant Staph aureus and susceptible Staph aureus strains. Its product candidate, CF-404 is used for the treatment of human influenza, including seasonal and pandemic varieties. It focuses on addressing drug-resistant infections using product candidates from its lysin and monoclonal antibody platforms that target conserved regions of either bacteria or viruses.
展开

Webull提供ContraFect Corp的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。